Aptevo Therapeutics (APVO)
(Delayed Data from NSDQ)
$0.57 USD
-0.04 (-6.74%)
Updated Jun 18, 2024 04:00 PM ET
After-Market: $0.56 -0.01 (-1.58%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth A Momentum B VGM
Brokerage Reports
Aptevo Therapeutics Inc. [APVO]
Reports for Purchase
Showing records 41 - 60 ( 96 total )
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Publishes Positive Phase 1b APVO436 Data Showing Efficacy & RP2D Selected
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
2Q21: APVO436 Phase 1 Complete, Funded Through 3Q22
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Clean APVO436 Safety Supports Combo Rx, But We View Takeout as the Story
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
1Q21: Well-Funded Through 2022, APVO436 Progressing Through Dose Cohort 10
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Encouraging Preclinical Updates for APVO603 and APVO442 at AACR
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
4Q20: Well-Funded, Monetizes Ruxience Royalty, APVO436 in Dose Cohort 10
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Healthcare- Annual ROTH Conference: Cancer Panel Takeaways
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology: Invitation: Virtual 33rd Annual Roth Conference (March 15-17)
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
APVO436 Interim Phase 1/1b AML/MDS Details at ASH Show Efficacy & Safety
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
New ADAPTIR-FLEX Platform & Preclinical Prostate Cancer Candidate APVO442
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J